A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

NCT00000775 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)